NTLA
Price
$12.10
Change
-$0.08 (-0.66%)
Updated
Dec 23 closing price
58 days until earnings call
PRTA
Price
$15.33
Change
+$0.11 (+0.72%)
Updated
Dec 23 closing price
51 days until earnings call
Ad is loading...

NTLA vs PRTA

Header iconNTLA vs PRTA Comparison
Open Charts NTLA vs PRTABanner chart's image
Intellia Therapeutics
Price$12.10
Change-$0.08 (-0.66%)
Volume$1.79M
CapitalizationN/A
Prothena
Price$15.33
Change+$0.11 (+0.72%)
Volume$567.9K
CapitalizationN/A
NTLA vs PRTA Comparison Chart
Loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NTLA vs. PRTA commentary
Dec 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NTLA is a Hold and PRTA is a Hold.

Ad is loading...
COMPARISON
Comparison
Dec 24, 2024
Stock price -- (NTLA: $12.10 vs. PRTA: $15.33)
Brand notoriety: NTLA and PRTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NTLA: 59% vs. PRTA: 81%
Market capitalization -- NTLA: $1.23B vs. PRTA: $824.89M
NTLA [@Biotechnology] is valued at $1.23B. PRTA’s [@Biotechnology] market capitalization is $824.89M. The market cap for tickers in the [@Biotechnology] industry ranges from $363.61B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NTLA’s FA Score shows that 1 FA rating(s) are green whilePRTA’s FA Score has 0 green FA rating(s).

  • NTLA’s FA Score: 1 green, 4 red.
  • PRTA’s FA Score: 0 green, 5 red.
According to our system of comparison, NTLA is a better buy in the long-term than PRTA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NTLA’s TA Score shows that 4 TA indicator(s) are bullish while PRTA’s TA Score has 5 bullish TA indicator(s).

  • NTLA’s TA Score: 4 bullish, 4 bearish.
  • PRTA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, PRTA is a better buy in the short-term than NTLA.

Price Growth

NTLA (@Biotechnology) experienced а -9.57% price change this week, while PRTA (@Biotechnology) price change was +21.57% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.03%. For the same industry, the average monthly price growth was -2.09%, and the average quarterly price growth was +3.05%.

Reported Earning Dates

NTLA is expected to report earnings on Feb 20, 2025.

PRTA is expected to report earnings on Feb 13, 2025.

Industries' Descriptions

@Biotechnology (-1.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($1.23B) has a higher market cap than PRTA($825M). PRTA (-57.815) and NTLA (-60.315) have similar YTD gains . PRTA has higher annual earnings (EBITDA): -167.23M vs. NTLA (-527.52M). NTLA has more cash in the bank: 658M vs. PRTA (519M). PRTA has less debt than NTLA: PRTA (11.5M) vs NTLA (102M). PRTA has higher revenues than NTLA: PRTA (133M) vs NTLA (43.1M).
NTLAPRTANTLA / PRTA
Capitalization1.23B825M149%
EBITDA-527.52M-167.23M315%
Gain YTD-60.315-57.815104%
P/E RatioN/AN/A-
Revenue43.1M133M32%
Total Cash658M519M127%
Total Debt102M11.5M887%
FUNDAMENTALS RATINGS
NTLA vs PRTA: Fundamental Ratings
NTLA
PRTA
OUTLOOK RATING
1..100
7279
VALUATION
overvalued / fair valued / undervalued
1..100
30
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
10094
SMR RATING
1..100
9794
PRICE GROWTH RATING
1..100
9164
P/E GROWTH RATING
1..100
10094
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (30) in the Biotechnology industry is in the same range as PRTA (61). This means that NTLA’s stock grew similarly to PRTA’s over the last 12 months.

PRTA's Profit vs Risk Rating (94) in the Biotechnology industry is in the same range as NTLA (100). This means that PRTA’s stock grew similarly to NTLA’s over the last 12 months.

PRTA's SMR Rating (94) in the Biotechnology industry is in the same range as NTLA (97). This means that PRTA’s stock grew similarly to NTLA’s over the last 12 months.

PRTA's Price Growth Rating (64) in the Biotechnology industry is in the same range as NTLA (91). This means that PRTA’s stock grew similarly to NTLA’s over the last 12 months.

PRTA's P/E Growth Rating (94) in the Biotechnology industry is in the same range as NTLA (100). This means that PRTA’s stock grew similarly to NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NTLAPRTA
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 5 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
69%
MACD
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 5 days ago
78%
Bullish Trend 15 days ago
76%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 9 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VRLCX18.860.16
+0.86%
Voya Large Cap Growth Port R6
LEXCX62.480.14
+0.22%
Voya Corporate Leaders Trust B
CVSOX14.920.01
+0.09%
Calamos Market Neutral Income R6
HSSCX22.80N/A
N/A
Emerald Finance & Bking Innovt Fd C
GURAX32.37N/A
N/A
NAA Risk Managed Real Estate A

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-0.66%
VCYT - NTLA
69%
Closely correlated
+0.24%
EDIT - NTLA
68%
Closely correlated
-4.58%
BEAM - NTLA
65%
Loosely correlated
-1.07%
CRSP - NTLA
62%
Loosely correlated
-0.59%
PRME - NTLA
58%
Loosely correlated
-3.10%
More

PRTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRTA has been loosely correlated with PEPG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PRTA jumps, then PEPG could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRTA
1D Price
Change %
PRTA100%
+0.72%
PEPG - PRTA
53%
Loosely correlated
+7.16%
DNLI - PRTA
51%
Loosely correlated
-3.12%
RGNX - PRTA
46%
Loosely correlated
-3.15%
NTLA - PRTA
45%
Loosely correlated
-0.66%
BEAM - PRTA
44%
Loosely correlated
-1.07%
More